Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 1 of 1 for:    PROPEL-36
Previous Study | Return to List | Next Study

BEMPEG With Pembrolizumab vs Pembrolizumab Alone in Patients With Metastatic or Recurrent HNSCC (PROPEL-36)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT04969861
Recruitment Status : Not yet recruiting
First Posted : July 21, 2021
Last Update Posted : September 29, 2021
Sponsor:
Collaborators:
SFJ Pharmaceuticals, Inc.
Merck Sharp & Dohme Corp.
Information provided by (Responsible Party):
Nektar Therapeutics

Brief Summary:
This is a multicenter, randomized, open-label, Phase 2/3 study that will evaluate the efficacy and safety of bempegaldesleukin (BEMPEG; NKTR-214) combined with pembrolizumab compared with pembrolizumab monotherapy in patients with recurrent or metastatic HNSCC with positive PD-L1 expression (CPS ≥ 1).

Condition or disease Intervention/treatment Phase
Metastatic Head and Neck Cancer Recurrent Head and Neck Cancer Drug: Bempegaldesleukin Drug: Pembrolizumab Phase 2 Phase 3

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 500 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Phase 2/3, Randomized, Open-label Study to Compare Bempegaldesleukin (NKTR-214) Combined With Pembrolizumab vs. Pembrolizumab Alone in First-Line Treatment of Patients With Metastatic or Recurrent HNSCC With PD-L1 Expressing Tumors
Estimated Study Start Date : October 2021
Estimated Primary Completion Date : August 2025
Estimated Study Completion Date : May 2026

Resource links provided by the National Library of Medicine


Arm Intervention/treatment
Experimental: BEMPEG + Pembrolizumab
Bempegaldesleukin plus pembrolizumab every 3 weeks (q3w) for up to 35 cycles (approximately 2 years).
Drug: Bempegaldesleukin
Specified dose on specified days

Drug: Pembrolizumab
Pembrolizumab (anti-PD-1) will be dosed as per the pharmacy manual.

Active Comparator: Pembrolizumab Monotherapy
Pembrolizumab monotherapy q3w for up to 35 cycles (approximately 2 years).
Drug: Pembrolizumab
Pembrolizumab (anti-PD-1) will be dosed as per the pharmacy manual.




Primary Outcome Measures :
  1. Overall Survival [ Time Frame: Approximately 2 years ]
    To compare the overall survival (OS) of bempegaldesleukin plus pembrolizumab versus pembrolizumab monotherapy.

  2. Objective Response Rate [ Time Frame: Approximately 2 years ]
    To compare the objective response rate (ORR) of bempegaldesleukin plus pembrolizumab versus pembrolizumab monotherapy.


Secondary Outcome Measures :
  1. Progression-Free Survival [ Time Frame: Approximately 2 years ]
    To compare progression-free survival (PFS) of bempegaldesleukin plus pembrolizumab versus pembrolizumab monotherapy.

  2. Time to Deterioration [ Time Frame: Approximately 2 years ]

    The time from baseline to a ≥ 10-point decrease with confirmation by the subsequent visit of a ≥ 10-point deterioration from baseline in:

    • Global health status/quality of life assessment based on the European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ-C30).

    The EORTC QLQ-C30 is a 30-item questionnaire designed to assess the quality of life of cancer patients. All scale scores are linearly converted to range from 0 to 100. A higher total score indicates a better level of functioning.

    • Pain and Swallowing based on respective multi-item scales of EORTC QLQ head and neck cancer specific module (EORTC QLQ-H&N35).

    EORTC QLQ-H&N35 consists of 7 multi-item scales that assess pain, swallowing, senses, speech, social eating, social contact and sexuality. All scale scores are linearly converted to range from 0 to 100. A higher total score indicates increased severity of symptoms.


  3. Change in Global Health Status/Quality of Life [ Time Frame: Approximately 2 years ]
    To compare mean change from baseline in global health status/quality of life scale of EORTC QLQ-C30. The EORTC QLQ-C30 is composed of multi-item scales and single item measures. These include 5 functional scales (physical, role, emotional, cognitive, and social), 3 symptom scales (fatigue, nausea/vomiting, and pain), a global health status/HRQoL scale, and 6 single items (dyspnea, insomnia, appetite loss, constipation, diarrhea, and financial difficulties). Each of the multi-item scales includes a different set of items - no item occurs in more than one scale. All scale scores are linearly converted to range from 0 to 100. A higher total score indicates a better level of functioning.

  4. Percentage of Patients with Treatment-Emergent Adverse Events and Serious Adverse Events [ Time Frame: Screening baseline through end of study, approximately 2 years ]
    Compare the overall safety and tolerability based on assessments of treatment-emergent adverse events and serious adverse events



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Provide written, informed consent to participate in the study and follow the study procedures.
  • Male or female patients, age 18 years or older at the time of signing the informed consent form (ICF).
  • Have histologically or cytologically-confirmed recurrent or metastatic HNSCC that is considered incurable by local therapies.

    • No prior systemic therapy for recurrent or metastatic disease.
    • The eligible primary tumor locations are oropharynx, oral cavity, hypopharynx, and larynx.
    • Patients may not have a primary tumor site of nasopharynx (any histology) and/or unknown primary.
  • Have measurable disease based on RECIST 1.1 as determined by the local site Investigator.
  • Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.

Measure Description: GRADE - ECOG PERFORMANCE STATUS

0 - Fully active, able to carry on all pre-disease performance without restriction

1 - Restricted in physically strenuous activity but ambulatory and able to carry out work of a light or sedentary nature, e.g., light housework, office work

2- Ambulatory and capable of all selfcare but unable to carry out any work activities; up and about more than 50% of waking hours

• The tumor must have positive PD-L1 expression (i.e., CPS ≥1)

Exclusion Criteria:

  • Has disease that is suitable for local therapy administered with curative intent.
  • Has progressive disease within 6 months of completion of curatively intended systemic treatment for locoregionally advanced HNSCC.
  • Has had radiation therapy (or other non-systemic therapy) within 2 weeks prior to initiation of study drug
  • Has a life expectancy of less than 3 months and/or has rapidly progressing disease (e.g., tumor bleeding, uncontrolled tumor pain) as determined by the Investigator.
  • Has a known additional malignancy that is progressing or has required active treatment within 5 years prior to the first dose of study drug
  • Has an active autoimmune disease that has required systemic treatment in the past 2 years
  • Has a diagnosis of immunodeficiency or is receiving systemic steroid therapy
  • Use of an investigational agent or an investigational device within 28 days before the first dose of study drug.
  • Prior treatment with an anti PD-1, anti PD-L1, anti-PD-L2, or anti CTLA-4 antibody, agents that target IL-2 pathway, or any other antibody or drug specifically targeting T-cell co-stimulation or checkpoint pathways.

NOTE: Other protocol defined inclusion/exclusion criteria may apply


Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04969861


Contacts
Layout table for location contacts
Contact: Medical Affairs 855-482-8676 medicalaffairs@nektar.com

Sponsors and Collaborators
Nektar Therapeutics
SFJ Pharmaceuticals, Inc.
Merck Sharp & Dohme Corp.
Investigators
Layout table for investigator information
Study Director: Study Director Nektar Therapeutics
Layout table for additonal information
Responsible Party: Nektar Therapeutics
ClinicalTrials.gov Identifier: NCT04969861    
Other Study ID Numbers: 20-214-36
First Posted: July 21, 2021    Key Record Dates
Last Update Posted: September 29, 2021
Last Verified: September 2021

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by Nektar Therapeutics:
Head and Neck Cancer
Head and Neck Squamous-Cell Carcinoma
HNSCC
BEMPEG
Bempegaldesleukin
NKTR-214
Keytruda
Pembrolizumab
PROPEL-36
Additional relevant MeSH terms:
Layout table for MeSH terms
Head and Neck Neoplasms
Neoplasms by Site
Neoplasms
Pembrolizumab
Antineoplastic Agents, Immunological
Antineoplastic Agents